Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMBARK

- PMLiVE

J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication

Bayer symbol

Bayer bags FDA nod for early prostate cancer drug darolutamide

new competition in the market

- PMLiVE

Von der Leyen elected new European Commission president

Pledges green deal and universal healthcare for 500m citizens

- PMLiVE

$450m diagnostics sale will fuel more Syncona biotech funding

Radiopharmaceuticals firm sold to Braco Imaging

- PMLiVE

Encouraging early data for Amgen’s BiTE therapies

Including first-in-man data from prostate cancer drug

Bayer symbol

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga

- PMLiVE

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market

- PMLiVE

J&J’s Erleada cleared for early prostate cancer in Europe

Signals competiton for Xtandi

- PMLiVE

Astellas, Catalyst approvals set up record year for FDA approvals

2018 is already well ahead of last year's tally

- PMLiVE

Astellas makes another gene therapy play with Juventas deal

Targeting faecal incontinence, which affects 50m worldwide

- PMLiVE

Generic threat looms to J&J’s blockbuster Zytiga in US

Impact could also be felt by Pfizer

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links